The rationale for this study was to evaluate the feasibility of within-suite ⁸⁹Zr-labeled radiotracer PET/CT-guided biopsy performed without reinjection. Methods: From 2013 to 2016, 12 patients (7 men, 5 women; mean age, 61 y; range, 40–75 y) with metastatic prostate or breast carcinoma suspected either on imaging or because of biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using ⁸⁹Zr-labeled radiotracers (mean dose, 180 MBq; range, 126–189 MBq) targeting prostate-specific membrane antigen (n = 7) or human epidermal growth factor receptor 2 (n = 5). Biopsy was performed within a PET/CT suite without radiotracer reinjection. Results: There were no complications in any biopsies, which were performed a mean of 6.2 d (range, 0–13 d) after injection of the radiotracer. The biopsy sites were bone (n = 7), pleura (n = 3), lymph nodes (n = 2), and liver (n = 2). On pathologic examination of the biopsy samples, all were positive for malignancy. The initial diagnostic imaging findings were concordant with the biopsy results. The additional radiation (mean dose–length product) due to the CT procedures was 1,581 mGy/cm (range, 379–2,686 mGy/cm). Conclusion: PET/CT-guided biopsy using ⁸⁹Zr-labeled radiotracers is safe and effective without tracer reinjection.

这项研究的基本原理是评估无需重新注射即可进行⁸⁹ Zr标记的放射性示踪剂PET / CT引导的活检的可行性。方法：从2013年到2016年，对12例因影像学检查或生化进展而怀疑有转移性前列腺癌或乳腺癌的患者（男7例，女5例；平均年龄61岁；范围40-75岁），经诊断后行了14次经皮活检PET / CT使用^89种Zr标记的放射性示踪剂（平均剂量180 MBq；范围126–189 MBq）靶向前列腺特异性膜抗原（n = 7）或人表皮生长因子受体2（n = 5）。活检是在PET / CT套件内进行的，无需重新注入放射性示踪剂。结果：活检中没有并发症，注射放射性示踪剂后平均进行6.2 d（范围0-13 d）。活检部位为骨骼（n = 7），胸膜（n = 3），淋巴结（n = 2）和肝脏（n = 2）。在对活检样品进行病理检查后，所有患者的恶性肿瘤均为阳性。最初的诊断影像学发现与活检结果一致。CT程序带来的额外辐射（平均剂量-长度乘积）为1,581 mGy / cm（范围379–2,686 mGy / cm）。结论：使用^89种Zr标记的放射性示踪剂进行PET / CT引导的活检是安全且有效的，无需重新注入示踪剂。